Dihexa
Synthetic Hexapeptide (HGF/c-Met activator)
Also known as: N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide
Last updated May 4, 2026
What is Dihexa?
You’ve probably seen the claim: Dihexa is “millions of times more potent than BDNF.” Your instinct to be skeptical is correct. This is the most hyped and least proven compound in the cognitive peptide space — and the foundational research has been seriously compromised.
Dihexa is a synthetic hexapeptide designed to activate the HGF/c-Met receptor system, which is involved in neural connectivity and synapse formation. It was developed at Washington State University. The original research claimed extraordinary potency in promoting cognitive function in animal models. However, the foundational researcher (Dr. Joseph Harding) has had key research retracted and other papers investigated for data integrity concerns. This doesn’t necessarily mean the compound doesn’t work — but it means the evidence base consumers are relying on is compromised at its foundation.
What Does the Research Actually Show?
Animal studies showed enhanced cognitive function and neural connectivity through activation of the HGF/c-Met receptor system, which is involved in synapse formation. But the primary researcher’s work has been called into question, so the magnitude of the reported effect should be treated with skepticism.
How Is Dihexa Administered?
There is no FDA-approved or clinically validated Dihexa protocol, and unlike most peptides on this site, there is no published human dosing data of any kind. The dosing approaches reported in biohacker communities are extrapolated from rodent studies whose foundational research has been retracted.
Practitioner-reported approaches:
- Route: Oral or sublingual most commonly; intranasal sometimes mentioned. None of these routes has been validated for human use.
- Reported ranges: Community-reported doses range widely. Because there is no human pharmacokinetic data, there is no basis for translating rodent dosing to humans accurately.
- Frequency: Typically daily, often cycled.
What Are the Side Effects and Risks?
- Potential HGF/c-Met pathway risks including theoretical cancer concern (HGF/c-Met is implicated in tumor progression).
Who Should NOT Use Dihexa?
If you have a cancer history or active malignancy: The HGF/c-Met pathway that Dihexa activates is implicated in tumor progression. This is not a theoretical concern — it is a known oncology issue. HGF/c-Met inhibitors are an area of active cancer drug development precisely because activation of this pathway promotes tumor growth and metastasis. Anyone with a personal cancer history should not consider Dihexa.
If you are pregnant or breastfeeding: No safety data exists. Absolute contraindication.
If you are not comfortable with compromised foundational research: Dihexa’s mechanism story rests on research from a lab that has had a key paper retracted and other papers under investigation. If you can’t make peace with that as a foundation for what you put in your body, that is a reasonable position — and Dihexa is not the right compound for you.
If you are unwilling to accept high uncertainty: This is the least-proven compound on our site. Zero human trials. Compromised preclinical work. Unstudied long-term safety. If you want a peptide where the evidence supports confident decision-making, this is not it.
If this is your first cognitive peptide: Don’t start here. Semax and Selank have substantially stronger evidence profiles, longer track records and better-characterized safety. If you’re new to cognitive peptides, those are the right starting points.
Before You Start: Get Baseline Labs
We recommend baseline lab work before starting any peptide protocol so you and your provider can track changes. Key markers include CBC, CMP, liver function panel (ALT, AST) and a baseline cognitive assessment with your provider.
Ask your provider about ordering these labs, or search for direct-to-consumer lab testing services in your area.
Order at-home labs from Everlywell →Lab recommendations are the same regardless of which service you use.
- 1Are you familiar with the retraction issues surrounding Dihexa’s foundational research?
- 2Given the lack of human trials, what is your clinical rationale for prescribing this?
- 3How do you assess the HGF/c-Met pathway cancer risk?
- 4What monitoring would you recommend?
- 5Have you seen results in your patients, and how do you distinguish that from placebo?
Is Dihexa Legal in 2026?
Not FDA-approved. Removed from Category 2 effective April 22, 2026. PCAC review scheduled at the second of two PCAC meetings, to be held before February 2027 — alongside GHK-Cu, LL-37, Melanotan II, and PEG-MGF. Compounding cannot resume until after PCAC review and a final FDA determination adds Dihexa to the 503A bulks list.
A note on the regulatory pathway: even if PCAC reviews Dihexa favorably, the underlying evidence base — retracted foundational research, no human safety trials, an unresolved cancer risk through HGF/c-Met activation — means Dihexa is unlikely to develop a meaningful legitimate telehealth pathway regardless of compounding eligibility. The questions a regulatory pathway can answer are different from the questions a thoughtful provider would ask before prescribing.
How Do I Get Dihexa Through a Legitimate Provider?
PeptideClarity has not identified evaluated providers for Dihexa given the current regulatory landscape. If conditions change and providers meet PeptideClarity Evaluated criteria, this section will reflect that.